34 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: the design of potent histamine H3 receptor antagonists.
The James Black Foundation
From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.
The James Black Foundation
Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
Merck Research Laboratories
Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands.
Jagiellonian University Medical College
4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
Glaxosmithkline
Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Freie Universit£T Berlin
Influence of bulky substituents on histamine h(3) receptor agonist/antagonist properties.
Freie Universit£T Berlin
Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE.
De Novo Pharmaceuticals
N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.
Jagiellonian University Medical College
Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.
National Institute of Mental Health
The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists.
Merck Research Laboratories
Verongamine, a Novel Bromotyrosine-Derived Histamine H3-Antagonist from the Marine Sponge Verongula gigantea
TBA
Novel imidazole-based histamine H3 antagonists.
Johnson & Johnson Pharmaceutical Research & Development
Total synthesis and biological evaluation of the marine bromopyrrole alkaloid dispyrin: elucidation of discrete molecular targets with therapeutic potential.
Vanderbilt University
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
The Schering Plough Research Institute
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
The Schering Plough Research Institute
Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine.
The Schering Plough Research Institute
Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template.
The Schering Plough Research Institute
Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H(3) receptor antagonists.
The James Black Foundation
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.
Palack£
4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor.
Schering-Plough Research Institute
Novel H3 receptor antagonists. Sulfonamide homologs of histamine.
Schering-Plough Research Institute
Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo.
Schering-Plough Research Institute